Download PDF
Klinische Neurophysiologie 2003; 34(4): 176-181
DOI: 10.1055/s-2003-812579
Originalia
© Georg Thieme Verlag Stuttgart · New York

Stellenwert der Positronenemissionstomographie (PET) in der Epilepsiediagnostik

Ranking of Positron Emission Tomography (PET) in Epilepsy DiagnosticsM.  J.  Koepp1 , A.  Hammers1
  • 1Department of Clinical and Experimental Epilepsy, Institute of Neurology, and National Hospital for Neurology and Neurosurgery, London, and MRC Clinical Sciences Centre, Hammersmith Hospital, London, UK
Further Information

Publication History

Publication Date:
09 January 2004 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Untersuchungen mittels Positronenemissionstomographie (PET) haben zum pathophysiologischen und biochemischen Verständnis fokaler und generalisierter Epilepsien wesentlich beigetragen. H2 15O PET erlaubt Aussagen zum regionalen zerebralen Blutfluss (rZBF) und 18F-Fluorodeoxyglukose(FDG)-PET zum Glukosestoffwechsel. Iktale PET-Aufnahmen mit H2 15O sind wegen der 2-minütigen Halbwertszeit üblicherweise nicht planbar. Iktale 18F-FDG-PET-Aufnahmen sind wegen der protrahierten Aufnahme von FDG schwer zu interpretieren. Untersuchungen des rZBF und Glukosestoffwechsels geben nur indirekte Hinweise auf synaptische Aktivität. Neurotransmitter sind direkt verantwortlich für die Steuerung neuronaler Aktivität und PET erlaubt die quantitative Erfassung spezifischer Liganden-Rezeptor-Verhältnisse, die für die Entstehung und Weiterleitung epileptischer Aktivität von Bedeutung sind. Klinisch von Bedeutung sind: 1. 11C-Flumazenil (FMZ), das den GABAA-Rezeptor darstellt, und 2. 11C-Diprenorphin (DPN), das mit ähnlicher Affinität an μ-, κ- und δ-Opioidrezeptoren bindet. Die Koregistrierung struktureller Informationen ist zur genauen Interpretation funktioneller PET-Daten notwendig. Falls pathologische Strukturveränderungen in der MRT vorliegen, wie beispielsweise Hippokampussklerosen, muss für Teilvolumeneffekte korrigiert werden. Teilvolumeneffekte sind nichtlinear und betreffen bevorzugt kleinere Strukturen, so dass diese eine scheinbare Aktivitätsminderung oder sogar Aktivitätssteigerung („spill-over”) aufweisen. In dieser Übersichtsarbeit stellen wir zunächst PET-Untersuchungen bei idiopathisch-generalisierten Epilepsien (IGE) vor, gefolgt von einer nach Glukosestoffwechsel, Blutfluss und Neurotransmitterveränderungen gegliederten Auflistung von PET-Untersuchungen bei fokalen Epilepsiesyndromen.

Abstract

Studies using positron emission tomography (PET) have advanced our pathophysiological and biochemical understanding of focal and generalised epilepsies. H2 15O PET allows quantification of cerebral blood flow (rCBF), and 18F-fluorodeoxyglucose (FDG)-PET quantification of cerebral glucose metabolism. Ictal H2 15O PET studies are difficult because of its short half-life (2 min), ictal 18F-FDG-PET are difficult to interpret due to its prolonged uptake. H2 15O and 18F-FDG-PET are only indirect markers of neuronal activity. Neurotransmitters are directly responsible for modulating synaptic activity and PET allows quantification of specific ligand-receptor relationships which are important for epileptogenesis and spread of epileptic activity. Clinically important are: (1) 11C-flumazenil (FMZ), which images GABAA-receptors, and (2) 11C-diprenorphin (DPN), which has similar affinity to μ-, κ- and δ-opioid receptors. Co-registration of structural information is essential for the exact interpretation of functional PET data. Correction for partial volume effects is important if there are structural pathological changes, e. g. hippocampal sclerosis. Partial volume effects are non-linear and are of particular importance for small structures, leading to under- or even overestimation (spill-over) of true activity. In this review, we first present PET studies in idiopathic generalised epilepsies, followed by a summary of PET studies investigating glucose metabolism, rCBF and neurotransmitter changes in focal epilepsies.

Key words

PET - rCBF - glucose metabolism - neurotransmitter - epilepsies

Literatur

  • 1 Prevett M C, Duncan J S, Jones T, Fish D R, Brooks D J. Demonstration of thalamic activation during typical absence seizures using H2 15O and PET.  Neurology. 1995;  45 1396-1402
    CrossrefPubMedGoogle Scholar
  • 2 Koepp M J, Duncan J S. Positron emission tomography in idiopathic generalized epilepsy: Imaging beyond structure. In: Schmitz B, Sander T (eds) Juvenile myoclonic epilepsy: The Janz syndrome. London; Wrightson 2000: 91-99
    Google Scholar
  • 3 Koepp M J, Duncan J S. PET: Opiate neuroreceptor mapping. In: Henry TR, Duncan JS, Berkovic SF (eds) Functional imaging in the epilepsies. Philadelphia; Lippincott Williams & Wilkins 2000: 145-155
    Google Scholar
  • 4 Henry T R. PET: Cerebral blood flow and glucose metabolism - Presurgical localization. In: Henry TR, Duncan JS, Berkovic SF (eds) Functional imaging in the epilepsies. Philadelphia; Lippincott Williams & Wilkins 2000: 105-120
    Google Scholar
  • 5 Knowlton R C, Laxer K D, Ende G, Hawkins R A, Wong S T, Matson G B. et al . Presurgical multimodality neuroimaging in electroencephalographic lateralized temporal lobe epilepsy.  Ann Neurol. 1997;  42 829-837
    CrossrefPubMedGoogle Scholar
  • 6 Koutroumanidis M, Hennessy M J, Seed P T, Elwes R D, Jarosz J, Morris R G. et al . Significance of interictal bilateral temporal hypometabolism in temporal lobe epilepsy.  Neurology. 2000;  54 1811-1821
    PubMedGoogle Scholar
  • 7 Dupont S, Semah F, Clemenceau S, Adam C, Baulac M, Samson Y. Accurate prediction of postoperative outcome in mesial temporal lobe epilepsy: a study using positron emission tomography with 18fluorodeoxyglucose.  Arch Neurol. 2000;  57 1331-1336
    CrossrefPubMedGoogle Scholar
  • 8 Knowlton R C, Laxer K D, Klein G, Sawrie S, Ende G, Hawkins R A. et al . In vivo hippocampal glucose metabolism in mesial temporal lobe epilepsy.  Neurology. 2001;  57 1184-1190
    PubMedGoogle Scholar
  • 9 Bogaert P Van, David P, Gillain A, Wikler D, Damhaut P, Scalais E. et al . Perisylvian dysgenesis. Clinical, EEG, MRI and glucose metabolism features in 10 patients.  Brain. 1998;  121 2229-2238
    CrossrefPubMedGoogle Scholar
  • 10 Chugani H T, Shields W D, Shewmon D A, Olson D M, Phelps M E, Peacock W J. Infantile spasms: I. PET identifies focal cortical dysgenesis in cryptogenic cases for surgical treatment.  Ann Neurol. 1990;  27 (4) 406-413
    CrossrefPubMedGoogle Scholar
  • 11 Savic I, Persson A, Roland P, Paulis S, Sedvall G, Widen L. In-vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci.  Lancet. 1988;  2 863-866
    PubMedGoogle Scholar
  • 12 Juhász C, Chugani D C, Muzik O, Watson C, Shah J, Shah A. et al . Electroclinical correlates of flumazenil and fluorodeoxyglucose PET abnormalities in lesional epilepsy.  Neurology. 2000;  55 825-834
    PubMedGoogle Scholar
  • 13 Koepp M J, Richardson M P, Labbé C, Brooks D J, Cunningham V J, Ashburner J. et al . 11C-flumazenil PET, volumetric MRI, and quantitative pathology in mesial temporal lobe epilepsy.  Neurology. 1997;  49 (3) 764-773
    PubMedGoogle Scholar
  • 14 Ryvlin P, Bouvard S, Bars D le, Lamérie G de, Grégoire M C, Kahane P. et al . Clinical utility of flumazenil-PET versus [18F] fluorodeoxyglucose-PET and MRI in refractory partial epilepsy. A prospective study in 100 patients.  Brain. 1998;  121 2067-2081
    CrossrefPubMedGoogle Scholar
  • 15 Ryvlin P, Bouvard S, Bars D le, Mauguiere F. Transient and falsely lateralizing flumazenil-PET asymmetries in temporal lobe epilepsy.  Neurology. 1999;  53 (8) 1882-1885
    PubMedGoogle Scholar
  • 16 Hand K S, Baird V H, Paesschen W Van, Koepp M J, Revesz T, Thom M. et al . Central benzodiazepine receptor autoradiography in hippocampal sclerosis.  Br J Pharmacol. 1997;  122 (2) 358-364
    CrossrefPubMedGoogle Scholar
  • 17 Koepp M J, Hand K S, Labbé C, Richardson M P, Paesschen W Van, Baird V H. et al . In vivo [11C]flumazenil-PET correlates with ex vivo [3H]flumazenil autoradiography in hippocampal sclerosis.  Ann Neurol. 1998;  43 (5) 618-626
    CrossrefPubMedGoogle Scholar
  • 18 Hammers A, Koepp M J, Labbé C, Brooks D J, Thom M, Cunningham V J. et al . Neocortical abnormalites of [11C]-flumazenil PET in mesial temporal lobe epilepsy.  Neurology. 2001;  56 897-906
    PubMedGoogle Scholar
  • 19 Szelies B, Weber-Luxenburger G, Mielke R, Pawlik G, Kessler J, Pietrzyk U. et al . Interictal hippocampal benzodiazepine receptors in temporal lobe epilepsy: comparison with coregistered hippocampal metabolism and volumetry.  Eur J Neurol. 2000;  7 (4) 393-400
    CrossrefPubMedGoogle Scholar
  • 20 Lamusuo S, Pitkänen A, Jutila L, Ylinin A, Partanen K, Kälviäinen R. et al . [11C]Flumazenil binding in the medial temporal lobe in patients with temporal lobe epilepsy. Correlation with hippocampal MR volumetry, T2 relaxometry, and neuropathology.  Neurology. 2000;  54 2252-2260
    PubMedGoogle Scholar
  • 21 Koepp M J, Hammers A, Labbé C, Wörmann F G, Brooks D J, Duncan J S. 11C-flumazenil PET in patients with refractory temporal lobe epilepsy and normal MRI.  Neurology. 2000;  54 332-339
    CrossrefPubMedGoogle Scholar
  • 22 Hammers A, Koepp M J, Hurlemann R, Richardson M P, Brooks D J, Duncan J S. Abnormalities of grey and white matter [11C] flumazenil binding in temporal lobe epilepsy with normal MRI.  Brain. 2002;  125 2257-2271
    CrossrefPubMedGoogle Scholar
  • 23 Savic I, Thorell J O, Roland P. [11C]Flumazenil positron emission tomography visualises frontal epileptogenic regions.  Epilepsia. 1995;  36 1225-1232
    CrossrefPubMedGoogle Scholar
  • 24 Muzik O, Silva E A da, Juhasz C, Chugani D C, Shah J, Nagy F. et al . Intracranial EEG versus flumazenil and glucose PET in children with extratemporal lobe epilepsy.  Neurology. 2000;  54 (1) 171-179
    CrossrefPubMedGoogle Scholar
  • 25 Juhász C, Chugani D C, Muzik O, Shah A, Shah J, Watson C. et al . Relationship of flumazenil and glucose PET abnormalities to neocortical epilepsy surgery outcome.  Neurology. 2001;  56 1650-1658
    CrossrefPubMedGoogle Scholar
  • 26 Richardson M P, Koepp M J, Brooks D J, Duncan J S. 11C-flumazenil PET in neocortical epilepsy.  Neurology. 1998;  51 485-492
    PubMedGoogle Scholar
  • 27 Hammers A, Koepp M J, Richardson M P, Hurlemann R, Brooks D J, Duncan J S. Grey and white matter flumazenil binding in neocortical epilepsy with normal MRI. A PET study of 44 patients.  Brain. 2003;  126 1300-1318
    CrossrefPubMedGoogle Scholar
  • 28 Richardson M P, Friston K J, Sisodiya S M, Koepp M J, Ashburner J, Free S L. et al . Cortical grey matter and benzodiazepine receptors in malformations of cortical development. A voxel-based comparison of structural and functional imaging data.  Brain. 1997;  120 (Pt 11) 1961-1973
    CrossrefPubMedGoogle Scholar
  • 29 Hammers A, Koepp M J, Richardson M P, Labbé C, Brooks D J, Cunningham V J. et al . Central benzodiazepine receptors in malformations of cortical development. A quantitative study.  Brain. 2001;  124 1555-1565
    CrossrefPubMedGoogle Scholar
  • 30 Koepp M J, Richardson M P, Brooks D J, Duncan J S. Focal cortical release of endogenous opioids during reading-induced seizures.  Lancet. 1998;  352 952-955
    CrossrefPubMedGoogle Scholar
  • 31 Chugani D C, Chugani H T. PET: mapping of serotonin synthesis.  Adv Neurol. 2000;  83 165-171
    PubMedGoogle Scholar
  • 32 Fedi M, Reutens D, Okazawa H, Andermann F, Boling W, Dubeau F. et al . Localizing value of alpha-methyl-L-tryptophan PET in intractable epilepsy of neocortical origin.  Neurology. 2001;  57 1629-1636
    PubMedGoogle Scholar
  • 33 Natsume J, Kumakura Y, Bernasconi N, Soucy J P, Nakai A, Rosa P, Fedi M. et al . Alpha-[11C] methyl-L-tryptophan and glucose metabolism in patients with temporal lobe epilepsy.  Neurology. 2003;  60 756-761
    PubMedGoogle Scholar
  • 34 Toczek M T, Carson R E, Lang L, Ma Y, Spanaki M V, Der M G. et al . PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy.  Neurology. 2003;  60 749-756
    CrossrefPubMedGoogle Scholar
  • 35 Kumlien E, Hartvig P, Valind S, Oye I, Tedroff J, Langstrom B. NMDA-receptor activity visualized with (S)-[N-methyl-11C]ketamine and positron emission tomography in patients with medial temporal lobe epilepsy.  Epilepsia. 1999;  40 (1) 30-37
    PubMedGoogle Scholar
  • 36 Kumlien E, Nilsson A, Hagberg G, Langstrom B, Bergstrom M. PET with 11C-deuterium-deprenyl and 18F-FDG in focal epilepsy.  Acta Neurol Scand. 2001;  103 (6) 360-366
    CrossrefPubMedGoogle Scholar
  • 37 Banati R B, Goerres G W, Myers R, Gunn R N, Turkheimer F E, Kreutzberg G W. et al . [11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen's encephalitis.  Neurology. 1999;  53 (9) 2199-2203
    PubMedGoogle Scholar
  • 38 Pennell P B. PET: Cholinergic neuroreceptor mapping. In: Henry TR, Duncan JS, Berkovic SF (eds) Functional imaging in the epilepsies. Philadelphia; Lippincott Williams & Wilkins 2000: 157-163
    Google Scholar

Dr. Matthias J. Koepp

Chalfont Centre for Epilepsy · Chalfont St. Peter

Chesham Lane · Gerrards Cross

Buckinghamshire SL9 0RJ · U. K.

Email: mkoepp@ion.ucl.ac.uk

      >